title: Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
abstract: BACKGROUND
  Resistance to trastuzumab is often observed in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and has been shown to involve multiple potential mechanisms. We examined the ability of microarray analyses to determine the potential markers of pathological complete response (pCR).
  
  
  METHODS
  We conducted an analysis of tumours from 38 patients with locally advanced HER2-positive breast cancer who had received trastuzumab combined with docetaxel. Quantitative reverse transcriptase (RT)-PCR was used to assess the expression of 30 key genes; microarray analyses were carried out on 25 tumours to identify a prognostic gene expression profile, with 13 blinded samples used to validate the identified profile.
  
  
  RESULTS
  No gene was found to correlate with response by RT-PCR. The microarray analysis identified a gene expression profile of 28 genes, with 12 upregulated in the pCR group and 16 upregulated in non-pCR. The leave-one-out cross-validation test exhibited 72% accuracy, 86% specificity, and 55% sensitivity. The 28-gene expression profile classified the 13 validation samples with 92% accuracy, 89% specificity, and 100% sensitivity.
  
  
  CONCLUSIONS
  Our results suggest that genes not involved in classical cancer pathways such as apoptosis or DNA repair could be involved in responses to a trastuzumab-docetaxel-based regimen. They also describe for the first time a gene expression signature that predicts trastuzumab response.
authors.affiliation: Centre Georges François Leclerc, IFR-Santé-STIC, Dijon Cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Végran
authors.forename: R
authors.initials: R
authors.lastname: Boidot
authors.forename: B
authors.initials: B
authors.lastname: Coudert
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: L
authors.initials: L
authors.lastname: Arnould
authors.forename: J
authors.initials: J
authors.lastname: Garnier
authors.forename: S
authors.initials: S
authors.lastname: Causeret
authors.forename: J
authors.initials: J
authors.lastname: Fraise
authors.forename: D
authors.initials: D
authors.lastname: Dembélé
authors.forename: S
authors.initials: S
authors.lastname: Lizard-Nacol
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000077143:Docetaxel; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human